As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
17 Analysts have issued a Galapagos forecast:
17 Analysts have issued a Galapagos forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 276 276 |
53%
53%
|
|
| Gross Profit | 241 241 |
10%
10%
|
|
| EBITDA | -251 -251 |
96%
96%
|
|
| EBIT (Operating Income) EBIT | -333 -333 |
75%
75%
|
|
| Net Profit | -284 -284 |
184%
184%
|
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
| Head office | Belgium |
| CEO | Henry Gosebruch |
| Employees | 704 |
| Founded | 1999 |
| Website | www.glpg.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


